

## Special Issue

# Therapeutic Approaches for Myeloproliferative Neoplasms

### Message from the Guest Editors

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell myeloid neoplasms that are characterized by the proliferation and preserved differentiation of myeloid cell lineages. Excluding *BCR-ABL1*-positive chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) are the most frequent MPNs. Constitutive activation of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT) signaling pathway due to acquired somatic mutations in the *JAK2*, *calreticulin* or *MPL* genes may drive the course of MPNs. Traditional treatment approaches for PV and ET focus on the prevention of thrombotic events with aspirin along with antiproliferative agents. Treatment strategies for MF are driven by clinical presentations such as anemia and/or splenomegaly. In this Special Issue, we aim to collect studies and reviews about the therapeutic landscape of MPNs, with a particular focus on new treatments.

### Guest Editors

Dr. Massimo Breccia

Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy

Dr. Francesca Palandri

Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

### Deadline for manuscript submissions

closed (30 April 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/176189](https://mdpi.com/si/176189)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)